– Reuters
Amneal Pharmaceuticals Stock Gaines: It Raised FY23 Outlook On Prescription Trends, Pricing Levels Strength
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $599 million, an increase of 7% Y/Y, beating the consensus of $5